A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

[1]  M. Hayden,et al.  Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research , 2017, Progress in Neurobiology.

[2]  R. Zivadinov,et al.  Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study , 2017, Multiple sclerosis.

[3]  H. Butzkueven,et al.  A genetic basis for multiple sclerosis severity: Red herring or real? , 2016, Molecular and cellular probes.

[4]  D. Centonze,et al.  The heritage of glatiramer acetate and its use in multiple sclerosis , 2016, Multiple Sclerosis and Demyelinating Disorders.

[5]  Daniel S. Himmelstein,et al.  Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. , 2016, JAMA Neurology.

[6]  H. Hartung,et al.  Steering through complexity: management approaches in multiple sclerosis. , 2016, Current opinion in neurology.

[7]  L. Leocani,et al.  Stroop event-related potentials as a bioelectrical correlate of frontal lobe dysfunction in multiple sclerosis , 2016, Multiple Sclerosis and Demyelinating Disorders.

[8]  Mat D. Davis,et al.  Time Course of Glatiramer Acetate Efficacy in Relapsing-Remitting Multiple Sclerosis Patients in the Glatiramer Acetate Low-Frequency Administration (GALA) Study (S51.006) , 2016 .

[9]  X. Montalban,et al.  Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study , 2016, The Pharmacogenomics Journal.

[10]  O. Favorova,et al.  Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs , 2016, Pharmacogenetics and genomics.

[11]  M. Hayden,et al.  Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition , 2016, Journal of Neuroimmunology.

[12]  M. Sormani,et al.  Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[13]  Jill A Hollenbach,et al.  The immunogenetics of multiple sclerosis: A comprehensive review. , 2015, Journal of autoimmunity.

[14]  A. Alcina,et al.  Genome-wide significant association with seven novel multiple sclerosis risk loci , 2015, Journal of Medical Genetics.

[15]  T. Raj,et al.  A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity , 2015, Annals of neurology.

[16]  C. Ford,et al.  Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis , 2015, Expert review of neurotherapeutics.

[17]  Maxim N. Artyomov,et al.  Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids , 2015, Scientific Reports.

[18]  S. Inoue,et al.  Autophagy-independent functions of UVRAG are essential for peripheral naive T-cell homeostasis , 2015, Proceedings of the National Academy of Sciences.

[19]  R. Aharoni.  Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review. , 2014, Journal of autoimmunity.

[20]  Alexander V. Favorov,et al.  Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. , 2014, Pharmacogenomics.

[21]  A. Waldman,et al.  Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials , 2014, Multiple sclerosis international.

[22]  D. Arnold,et al.  A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis , 2014, Journal of Neurology.

[23]  S. Mahurkar,et al.  Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. , 2014, Autoimmunity reviews.

[24]  Fadi Towfic,et al.  Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic , 2014, PLoS ONE.

[25]  S. Buyske,et al.  HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis. , 2013, Multiple sclerosis and related disorders.

[26]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[27]  L. Leocani,et al.  Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome , 2013, Multiple sclerosis.

[28]  Steven L. Scott,et al.  Predicting the Present with Bayesian Structural Time Series , 2013, Int. J. Math. Model. Numer. Optimisation.

[29]  R. Zivadinov,et al.  Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis , 2013, Annals of neurology.

[30]  Martin Daumer,et al.  Onset of secondary progressive phase and long-term evolution of multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  Joseph Avruch,et al.  Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. , 2012, Physiological reviews.

[32]  Alexander V. Favorov,et al.  Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy , 2011, Molecular Biology.

[33]  Richard Nicholas,et al.  Trends in annualized relapse rates in relapsing–remitting multiple sclerosis and consequences for clinical trial design , 2011, Multiple sclerosis.

[34]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[35]  H. Weiner,et al.  Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments , 2011, Journal of Neuroimmunology.

[36]  Jeffrey A. Cohen,et al.  Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis , 2011, Annals of neurology.

[37]  S. Hauser,et al.  Aggregation of multiple sclerosis genetic risk variants in multiple and single case families , 2011, Annals of neurology.

[38]  William S Bush,et al.  Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. , 2010, American journal of human genetics.

[39]  Xiao-Lin Wu,et al.  Bayesian model averaging for evaluation of candidate gene effects , 2010, Genetica.

[40]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[41]  M. Stephens,et al.  Bayesian statistical methods for genetic association studies , 2009, Nature Reviews Genetics.

[42]  Pablo Moscato,et al.  Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 , 2009, Nature Genetics.

[43]  B. Fridley.  Bayesian variable and model selection methods for genetic association studies , 2009, Genetic epidemiology.

[44]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[45]  J. Beckmann,et al.  Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers , 2007, Pharmacogenetics and genomics.

[46]  S. Martínez-Yélamos,et al.  Regression to the mean in multiple sclerosis , 2006, Multiple sclerosis.

[47]  M. Filippi,et al.  Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained , 2002, Neurology.

[48]  G. Coppola,et al.  HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis , 2001, Neurology.

[49]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[50]  Adrian E. Raftery,et al.  Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .

[51]  J S Wolinsky,et al.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.

[52]  E. George,et al.  APPROACHES FOR BAYESIAN VARIABLE SELECTION , 1997 .

[53]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[54]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[55]  Adrian E. Raftery,et al.  Bayesian Model Averaging: A Tutorial , 2016 .

[56]  M. Üner.  Handbook of Clinical Nanomedicine - Nanoparticles, Imaging, Therapy, and Clinical Applications , 2016 .

[57]  Jon S. B. de Vlieger,et al.  Non-Biological Complex Drugs , 2015, AAPS Advances in the Pharmaceutical Sciences Series.

[58]  J. Conner.  Copaxone ® in the era of biosimilars and nanosimilars , 2014 .

[59]  M. Vannucci,et al.  Advances in Statistical Bioinformatics: Bayesian Model Averaging for Genetic Association Studies , 2013 .

[60]  Alexander V. Favorov,et al.  Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. , 2012, Pharmacogenomics.

[61]  M. Sela,et al.  Cop 1 as a candidate drug for multiple sclerosis. , 1997, Journal of neural transmission. Supplementum.

[62]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.